^
Association details:
| Biomarker: | EGFR G719C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial
Published date:
10/12/2022
Excerpt:
Eligible patients had EGFR exon 18-mutant NSCLC and ECOG performance status 0–2....Patients received neratinib (240 mg po daily)....ORR was 31% overall and 26% in patients pretreated with TKIs (Table 1). Two of 7 patients with baseline CNS metastasis had a partial response (PR; median PFS 3.6 months; 95% CI 1.9–9.1 months). Long-lived responses were observed in 3 patients with G719A/X/C mutations (2 PR, 1 SD)....Neratinib monotherapy had meaningful activity in patients with EGFR exon 18-mutant NSCLC in SUMMIT; 31% of patients had a PR and most patients had prior TKIs.
Trial ID:
